HSBC Holdings’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.2M Sell
278,300
-237,500
-46% -$11.3M 0.01% 928
2025
Q4
$26.3M Buy
515,800
+374,400
+265% +$19.1M 0.01% 665
2025
Q3
$7.84M Sell
141,400
-173,400
-55% -$10.1M ﹤0.01% 1019
2025
Q2
$21.9M Hold
314,800
0.01% 676
2025
Q1
$21.9M Buy
314,800
+269,700
+598% +$22.3M 0.01% 682
2024
Q4
$3.87M Buy
+45,100
New +$4.88M ﹤0.01% 1226

Other funds holding NVO

HSBC Holdings's NVO Position: Q1 2026 in Review

HSBC Holdings increased its Novo Nordisk (NVO) stake by 96% in Q1 2026, buying an estimated $20.9M and bringing the position to 899,804 shares worth $32.7M. The position accounts for 0.02% of the portfolio, ranked #620.

HSBC Holdings first reported a position in NVO in Q3 2014 and has held it in 47 quarters since. The position peaked at $55M in Q2 2023. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • HSBC Holdings held 899,804 shares of Novo Nordisk worth $32.7M as of Q1 2026.
  • HSBC Holdings bought 440,571 Novo Nordisk shares in Q1 2026, an estimated $20.9M.
  • Novo Nordisk made up 0.02% of HSBC Holdings's portfolio in Q1 2026, its #620 holding.
  • HSBC Holdings first reported a position in Novo Nordisk in Q3 2014 and has held it in 47 quarters since.
  • HSBC Holdings's Novo Nordisk position peaked at $55M in Q2 2023.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.